Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Profit After Tax: 2017-2025

Historic Profit After Tax for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to -$36.8 million.

  • Dianthus Therapeutics' Profit After Tax fell 46.04% to -$36.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$126.4 million, marking a year-over-year decrease of 88.26%. This contributed to the annual value of -$85.0 million for FY2024, which is 94.95% down from last year.
  • Dianthus Therapeutics' Profit After Tax amounted to -$36.8 million in Q3 2025, which was down 16.24% from -$31.6 million recorded in Q2 2025.
  • Over the past 5 years, Dianthus Therapeutics' Profit After Tax peaked at -$7.1 million during Q1 2023, and registered a low of -$36.8 million during Q3 2025.
  • In the last 3 years, Dianthus Therapeutics' Profit After Tax had a median value of -$17.6 million in 2024 and averaged -$20.6 million.
  • Data for Dianthus Therapeutics' Profit After Tax shows a maximum YoY crashed of 168.59% (in 2024) over the last 5 years.
  • Dianthus Therapeutics' Profit After Tax (Quarterly) stood at -$10.1 million in 2022, then declined by 4.95% to -$10.6 million in 2023, then tumbled by 168.59% to -$28.5 million in 2024, then tumbled by 46.04% to -$36.8 million in 2025.
  • Its last three reported values are -$36.8 million in Q3 2025, -$31.6 million for Q2 2025, and -$29.5 million during Q1 2025.